Table 1.

Predictable analysis per cohort and outcome.

Analysisa	Outcomes
Exposed children in birth cohorts 2010 to 2015 compared to nonexposed children in birth cohorts 2010 to 2015, 2016, 2017, 2018, 2019, 2020, and 2021	Primary outcomes in the first year of life
Exposed children in birth cohorts 2010 to 2015 compared to nonexposed children in birth cohorts 2010 to 2015, 2016, and 2017	Primary outcomes in the first 5 years of life
Exposed children in birth cohorts 2016, 2017, 2018, 2019, 2020, and 2021 compared to nonexposed children in birth cohorts 2016, 2017, 2018, 2019, 2020, and 2021	Primary outcomes in the first year of life
Exposed children in birth cohorts 2016 and 2021 compared to nonexposed children in birth cohorts 2016 and 2017	Primary outcomes in the first 5 years of life
Nonexposed children in birth cohorts 2010 to 2015 compared to nonexposed children in birth cohorts 2016 to 2021	Secondary outcome profile of nonvaccinated children before and after the 2016 BCGb vaccination change
Children in birth cohorts 2010 to 2015, 2016, and 2017	Secondary outcomes of the mortality and morbidity profile of children under 5 years of age, and NHSc hospital and primary health care utilization profiles
Exposed children in birth cohorts 2010 to 2015 compared to exposed children in birth cohorts 2016, 2017, 2018, 2019, 2020, and 2021	Secondary outcomes of the mortality and morbidity incidence according to BCG strains administered per cohort in the first 5 years of life and first year of life
Exposed children in birth cohorts 2010 to 2015 compared to exposed children in birth cohorts 2016 and 2017	Secondary outcomes of the mortality and morbidity incidence according to BCG strains administered per cohort in the first 5 years of life

^aBetween 2010 and 2015, Bacillus Calmette-Guérin vaccine (BCG) coverage varied between 98.2% and 98.4%. In 2016, BCG coverage was 41.6%.

^bBCG: Bacillus Calmette-Guérin vaccine.

^cNHS: National Health Service.